Genetic Technologies Limited (ASX: $GTG) has announced a strategic joint sales & marketing agreement with US based Wellworks for You Inc. The agreement covers 750 employer groups and 2 million U.S. employees, integrating the geneType portfolio of tests into Wellworks' employee wellness solutions.
GTG's CEO, Simon Morriss, expressed excitement about the partnership, highlighting the potential for geneType Risk Assessment portfolio to differentiate both companies and propel GTG towards profitability. Wellworks CEO, Thomas Tegler, emphasized the commitment to personalized well-being solutions and the addition of geneType as a strong support to their wellness strategy.
Genetic Technologies (ASX: $GTG) has entered into a strategic joint sales & marketing agreement with Wellworks for You Inc., providing access to geneType tests for 2 million U.S. employees. The collaboration is expected to generate significant sales in the first year and marks a pivotal milestone in both companies' expansion strategies. The partnership aligns with Wellworks' commitment to personalized corporate wellness programs and GTG's pathway to profitability.